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Knowing the pathophysiology of trauma-induced coagulopathy is important for the management of severely injured
trauma patients. The aims of this review are to provide a summary of the recent advances in our understanding
of thrombosis and hemostasis following trauma and to discuss the pathogenesis of disseminated intravascular
coagulation (DIC) at an early stage of trauma. Local hemostasis and thrombosis respectively act to induce
physiological wound healing of injuries and innate immune responses to damaged-self following trauma.
However, if overwhelmed by systemic inflammation caused by extensive tissue damage and tissue hypoperfusion,
both of these processes foster systemic DIC associated with pathological fibrin(ogen)olysis. This is called DIC with
the fibrinolytic phenotype, which is characterized by the activation of coagulation, consumption coagulopathy,
insufficient control of coagulation, and increased fibrin(ogen)olysis. Irrespective of microvascular thrombosis, the
condition shows systemic thrombin generation as well as its activation in the circulation and extensive damage to
the microvasculature endothelium. DIC with the fibrinolytic phenotype gives rise to oozing-type non-surgical
bleeding and greatly affects the prognosis of trauma patients. The coexistences of hypothermia, acidosis, and
dilution aggravate DIC and lead to so-called trauma-induced coagulopathy.
He that would know what shall be must consider what has been.
The Analects of Confucius.Introduction
A half century ago, the concept of disseminated intravas-
cular coagulation (DIC) was ridiculed to be an abbrevi-
ation for ‘disseminated international confusion’ because
intravascular thrombosis was hardly ever found at autopsy.
At the end of the 1970s, however, Spero and colleagues [1]
correctly pronounced that DIC equals a sign that ‘death
is coming’. Since then, DIC has been recognized as an
independent disease entity caused by diverse insults, in-
cluding trauma and sepsis [2]. Recent findings suggest
that, under certain circumstances, local thrombosis as well
as hemostasis is a physiological process that constitutes an
intrinsic effector mechanism of innate immunity, which is
called immunothrombosis [3]. DIC is now believed to be a
result of the dysregulation of immunothrombosis. This* Correspondence: gando@med.hokudai.ac.jp
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waiver (http://creativecommons.org/publicdomasuggests that all insults, irrespective of whether they are
infectious (sepsis) or non-infectious (trauma), can cause
DIC when the control mechanisms of immunothrombosis
are overwhelmed.
However, the new theory of acute coagulopathy of
trauma shock (ACOTS) has completely denied DIC,
indicating that there is nothing to suggest a process of
DIC in the development of ACOTS and that the DIC
terminology to trauma is unhelpful and counterpro-
ductive [4,5]. Naturally, rebuttals to this concept have
been published [6]. The Scientific and Standardization
Committee (SSC) on DIC of the International Society on
Thrombosis and Haemostasis (ISTH) has published one
concept and six considerations for discussion about the
hemostatic changes in trauma [7]. After this announce-
ment, the SSC on DIC of the ISTH concluded that the
available data suggest that ACOTS is not a new concept
but a disease entity similar to or the same as DIC with the
fibrinolytic phenotype at an early stage of trauma [8]. Aentral. This is an Open Access article distributed under the terms of the Creative
mons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
nal work is properly credited. The Creative Commons Public Domain Dedication
in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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demonstrated that consumption coagulopathy, namely
DIC, predicts mortality, the prothrombin time inter-
national normalized ratio, and the activated partial
thromboplastin time (APTT) [9]. Fibrinolytic coagulop-
athy, which is independent of consumption coagulopa-
thy but often overlaps with this coagulopathy observed
in the analysis, indicates the existence of pathological
systemic hyperfibrin(ogen)olysis. Therefore, DIC with
the fibrinolytic phenotype, namely coexistence of DIC and
systemic hyperfibrin(ogen)olysis, could affect the outcome
of trauma patients [2,9]. This review will provide a sum-
mary of the recent advances in our understanding of
thrombosis and hemostasis following trauma and will
discuss the pathogenesis of DIC, especially DIC with
the fibrinolytic phenotype at an early stage of trauma.
Innate immunity, inflammation, and coagulation
at the site of injury
Both infectious (sepsis) and non-infectious insults (trauma)
can produce a systemic inflammatory response syndrome
(SIRS), characterized by systemic proinflammatory cytokine
release and generalized activation of leukocytes and the
endothelium, leading to multiple organ dysfunction syn-
drome (MODS). Recent advances in immunology led to
the recognition of common ligands involved in SIRS and
the understanding that the processes of SIRS are involved
in innate immunity [10]. Pathogen-associated molecular
patterns (PAMPs) are derived from microorganisms,
whereas damage-associated molecular patterns (DAMPs)
are molecules produced in stressed or damaged tissues in
connection with trauma, shock, ischemia, and reperfusion
[10]. The innate immune responses start following the
sensing PAMPs or DAMPs by pattern-recognition re-
ceptors, such as Toll-like receptors expressed on the
immunocompetent cells and endothelium. The sensed
danger signals activate both intracellular signal transduc-
tion pathways and plasma cascades, which together pro-
duce pro-inflammatory cytokines, further stimulating the
production of inflammatory biomarkers.
Close interactions between innate immunity, inflamma-
tion, and coagulation have been well recognized [11,12].
Innate immune cells have evolved cell-specific prothrom-
botic pathways that are activated after insults and operate
in intact blood vessels to protect hosts from non-self
(PAMPs) and altered-self (DAMPs). These processes are
called immunothrombosis, and the basic principles have
been reviewed [3]. During the responses to PAMPs and
DAMPs, monocytes and their microparticles express tis-
sue factor, which activates the extrinsic coagulation path-
way [13,14]. Neutrophils are recruited to both infectious
and non-infectious sites of inflammation and are activated
[15]. When activated, neutrophils release neutrophil extra-
cellular traps (NETs), which are composed of a matrix ofDNA, histones, nucleosomes, and antibacterial machinery,
including neutrophil elastase, which promotes thrombosis
[16]. Histones induce platelet activation and cause pro-
found thrombocytopenia [17]. Histones also promote
thrombin generation both by the recruitment of plate-
lets and by impairing thrombomodulin-dependent pro-
tein C activation [18,19]. NETs can also activate the
intrinsic coagulation pathway by activating FXII to
form FXIIa [20], which then promotes the activation
of complement pathways. The generated C3a and C5a
also promote thrombosis and platelet activation [21].
In addition, extracellular RNA derived from damaged cells
constitutes a procoagulant cofactor for the activation of
the FXII/FXI-induced coagulation pathway [22]. The
neutrophil elastase present on NETs induces the degrad-
ation and inactivation of tissue factor pathway inhibitor
(TFPI) [23,24] and the thrombomodulin expressed on the
endothelium [25,26].
All of these changes, including the activation of
coagulation and insufficient control of coagulation,
give rise to thrombosis at the sites of PAMP- and
DAMP-induced inflammation. This local thrombus
formation in microvessels impedes the dissemination
and tissue invasion of PAMPs and DAMPs as well as
pathogens and damaged cells themselves [3,24]. Severe
trauma and sepsis are both associated with DIC, a condition
that promotes the activation of coagulation and impairs
anticoagulation pathways in the systemic circulation [2,27].
In trauma, the thrombin that escapes into the circulation
from the injured sites is controlled by antithrombin, TFPI,
and thrombomodulin present in intact endothelial cells, as
depicted in the cell-based model of hemostasis [28].
However, when systemic inflammation caused by both
extensive injuries and shock overwhelms these control
mechanisms that restrict the hemostasis locally, DIC
ensues [28]. In the same manner, DIC results when
immunothrombosis is no longer able to restrict the
spread of pathogens or damaged cells at the inflamed
injured sites [3,28]. These processes are presented in
Figure 1.
Damage-associated molecular patterns hamper
the control mechanisms regulating coagulation
and activate coagulation following trauma
The major DAMPs released into the extracellular
environment following tissue injury are histones, mito-
chondrial DNA, nucleosomes, and high-mobility group box
1 (HMGB1) [29]. Within 30 minutes after trauma or imme-
diately after arrival to the emergency department, elevations
of the histones and HMGB1 levels have been demonstrated
in severely injured trauma patients [30-32]. Thousands of
fold-higher levels of mitochondrial DNA have also
been observed at a median of 93 minutes after trauma


























Figure 1 The pathophysiological processes of local hemostasis, immunothrombosis, and systemic disseminated intravascular
coagulation (DIC). Tissue injury promotes local hemostasis and wound healing. Tissue injury also induces microvascular fibrin thrombosis called
immunothrombosis to protect the host from altered-self (damage-associated molecular patterns; DAMPs) and to restrict the DAMPs in the injured
vascular compartment. DIC results when local hemostasis and immunothrombosis are no longer able to anchor thrombin or to restrict the spread
DAMPs at the injured site. NET, neutrophil extracellular trap; TFPI, tissue factor pathway inhibitor.
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and inflammatory cells at the site of injury promotes
the development of microvascular thrombosis [34].
An important point is that HMGB1 inhibits the anti-
coagulant protein C pathway mediated by the thrombin-
thrombomodulin complex and stimulates tissue factor
expression on monocytes. Histones also reduce the
cofactor activity of both soluble and endothelial thrombo-
modulin and impair protein C activation, leading to the
subsequent stimulation of plasma thrombin generation
[19]. Abrams and colleagues [32] observed significant
increases in soluble thrombomodulin and the thrombin
antithrombin complex (TAT) associated with IL-6
elevation immediately after histone infusion in a
mouse model. The same changes were demonstrated in
severely injured trauma patients in the study. In addition,
the circulating histone levels were significantly correlated
with both the soluble thrombomodulin and TAT levels in
trauma patients.
TNF-α and IL-1β are increased immediately after
trauma and remain elevated for several days, especially
in those with complicated DIC [5,35]. It was found that
TNF-α and IL-6 are elevated immediately after histone
infusion [32,36]. The early release of IL-6 suggests that it
was most likely released from presynthesized stores [32].
TNF-α and IL-1 have been shown to elicit tissue factor
formation and expression on the surface of monocytes
and endothelial cells. These inflammatory cytokines have
been shown to subsequently block the protein Canticoagulant pathway by downregulating thrombomo-
dulin and the endothelial protein C receptor (EPCR) on
the endothelium [37]. Furthermore, these inflammatory
cytokines activate neutrophils and endothelial cells,
leading to neutrophil elastase release from activated
neutrophils, which can cleave thrombomodulin, releasing
the soluble thrombomodulin from the endothelium in a
less active form [25,26,37,38].
These lines of evidence clearly suggest that both
DAMPs released from injured cells and tissues and
DAMP-induced inflammatory cytokines synergistically
hamper the mechanisms controlling coagulation by
protein C pathways and activate coagulation, leading to
systemic thrombin generation, namely DIC, immediately
after trauma.
Disseminated intravascular coagulation in trauma
and traumatic shock
Definition
The SSC on DIC of the ISTH defined DIC as follows: DIC
is an acquired syndrome characterized by the intravascular
activation of coagulation with loss of localization arising
from different causes. It can originate from and cause
damage to the microvasculature, which, if sufficiently
severe, can produce organ dysfunction [39]. The most
important points of the definition of DIC are ‘intravascular
activation of coagulation with loss of localization’ and
‘damage to the microvasculature’, which means thrombin
generation and its activation in the circulation and
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give rise to insufficient coagulation control.
Phenotypes
DIC can be subdivided into fibrinolytic (hemorrhagic)
and antifibrinolytic (thrombotic) phenotypes [2,5,7]
(Figure 2). The sepsis-induced DIC is the thrombotic
phenotype [27]. DIC at the early phase of trauma
shows the fibrinolytic phenotype, which contributes to
massive bleeding and is associated with a poor prognosis
[3,7,40]. DIC at the late phase of trauma has a thrombotic
phenotype that also affects the patient prognosis by leading
to the development of MODS [5,7,27]. The synergistic
activation of primary and secondary fibrin(ogen)olysis by
tissue-type plasminogen activator (t-PA) is considered to
be the cause of DIC with the fibrinolytic phenotype
[2], whereas plasminogen activator inhibitor-1 (PAI-1)-
mediated inhibition of fibrinolysis causes DIC with the
thrombotic phenotype [2,5,7,27]. Activation of coagulation
and depression of the inhibitory systems of coagulation
are common to both phenotypes.
Diagnosis
The ISTH and the Japanese Association for Acute Medicine
(JAAM) DIC diagnostic criteria have been prospectively
validated in patients with critical illness, including
trauma [39,41,42]. The JAAM scoring system has validity



















DIC with the thrombotic phenotype
Figure 2 The two phenotypes of disseminated intravascular coagulat
pathway as the initial step of the coagulation cascade and the presence of in
into the fibrinolytic (hemorrhagic) and antifibrinolytic (thrombotic) phenotype
olysis coexist. Annexin II expression on the promyelocytes increases the tissue
promyelocytic leukemia. PAI-1, plasminogen activator inhibitor-1; TFPI, tissue fcan diagnose DIC with higher sensitivity than the ISTH
scoring system. Furthermore, using the JAAM DIC
score on admission to the emergency department can
independently predict patient death and massive transfusion
in trauma cases [40,43,44].
Impairment of anticoagulation pathways
Tissue factor pathway inhibitor
The highly activated tissue factor-dependent pathway is
not sufficiently prevented by normal TFPI levels in DIC
patients after trauma, because neutrophil elastase cleaves
TFPI within the polypeptide that links the first and
second Kunitz domains [45]. This impairs the ability of
TFPI to neutralize both FXa and the tissue factor/FVIIa
complex. The finding suggests that tissue factor and tissue
factor/FVIIa complex are continuously formed at a rate
that normal TFPI inhibition cannot match [46]. Low levels
of antithrombin, protein C activity, and antigens have also
been repeatedly confirmed to be present from the early to
the late phases of DIC after trauma [7,40,44,47].
Thrombomodulin
Higher levels of neutrophil elastase and soluble throm-
bomodulin have also been confirmed in patients with
DIC [47,48]. Soluble thrombomodulin can be formed
by the limited proteolysis of endothelial cell membrane
thrombomodulin by neutrophil elastase without any















DIC with the fibrinolytic phenotype
ion (DIC). Although the activation of the tissue factor-dependent
sufficient anticoagulation systems are the same, DIC can be subdivided
s. In DIC with the fibrinolytic phenotype, DIC and systemic fibrin(ogen)
-type plasminogen activator (t-PA) activity in patients with acute
actor pathway inhibitor.
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endothelial injury [26]. Furthermore, early elevation of
TNF-α and IL-1β in DIC patients after trauma causes
thrombomodulin downregulation in the endothelium
[25,26,35]. Traumatic shock-induced hypoxia leads to a
reduction in thrombomodulin and the suppression of
thrombomodulin RNA in the endothelium [49,50]. There-
fore, the high soluble thrombomodulin levels in patients
with DIC suggest a loss of functional thrombomodulin in
the endothelium. Furthermore, soluble thrombomodulin
has only 20% of the activity of normal endothelial thrombo-
modulin [51].
Protein S and protein C
The thrombin-thrombomodulin complex activates pro-
tein C to generate activated protein C. For activated pro-
tein C to function, it must form a complex with both
protein S and EPCR. The anticoagulant activity of protein
S is neutralized by the formation of a complex with
complement C4b-binding protein (C4bBP). Increased
levels of C4bBP as a consequence of the acute-phase
reaction following inflammatory insults result in a
relative protein S deficiency, which contributes to the
procoagulant state and lethal DIC [52]. Lower levels
of protein S activity associated with thrombin generation
(prothrombin fragment 1 + 2 (PF1 + 2)) have already been
demonstrated in trauma patients immediately after arrival
to the emergency department [53].
Activated protein C is immediately inactivated by protease
inhibitors, such as the protein C inhibitors, α1-antitrypsin,
α2-antiplasmin, and α2-macroglobulin. In cases of DIC due
to trauma, lower protein C and protein S levels, relative
protein S deficiency, and impaired functions of both soluble
and endothelial thrombomodulin are all implicated in the
insufficient conversion of protein C to activated protein C
and the inability of activated protein C. Therefore, increases
in activated protein C levels do not indicate a shutoff of
thrombin generation. This fact was confirmed in patients
with severe sepsis, and the downregulation of endothelial
thrombomodulin and the dysfunction of the endothelium
were assumed to be the mechanisms responsible for this
finding [54]. In the reported study, the dissociation between
PF1 + 2 and the activated protein C levels was observed in
66% of patients. In fact, the elevated activated protein
C levels (~10 ng/mL) did not reach a concentration
(70 to 80 ng/mL) sufficient to inhibit thrombin generation
in severely injured trauma patients associated with tissue
hypoperfusion [54,55].
Antithrombin
Antithrombin inactivates thrombin and inhibits several
proteases of both the extrinsic and intrinsic coagulation
pathways, including FIXa, FXa, FXIa, and FXIIa. Therefore,
reductions of antithrombin can significantly influence thecoagulation processes, and are a potential risk factor for
thrombosis [56]. Insufficient levels of antithrombin
compared with the potential for thrombin generation
in the prothrombin complex concentrate induced DIC
in a pig model of coagulopathy with blunt liver injury
[57]. The severity of injury and tissue hypoperfusion
are major contributors to the reduction of antithrombin
in trauma [58,59]. Low antithrombin levels are associated
with thromboembolic complications, and the process con-
tinues to DIC [60]. Extremely low levels of antithrombin
could be observed in cases of trauma with DIC immedi-
ately after arrival to the emergency department [44,61].
This reduction of antithrombin persisted several days after
admission [44,61,62].
Two studies showed that a decreased ability to localize
hemostasis at the wound site and subsequent systemic
thrombin generation are the results of decreased anti-
thrombin levels in patients with coagulopathy immedi-
ately after trauma [63,64]. Similarly, a multiple regression
analysis demonstrated that the antithrombin levels are an
independent determinant of the high levels of soluble
fibrin, a marker of thrombin generation and activity, in
DIC patients after trauma [62]. Furthermore, a rat model
of DIC by Noble-Collip drum trauma and shock con-
firmed that the antithrombin levels negatively correlate
with thrombin generation (Gando, unpublished data).
These results clearly indicate that there is a much lower
availability of the TFPI, antithrombin/glycosaminoglycan,
and thrombomodulin/protein C systems for the regulation
of thrombin generation and its activation in patients
with DIC. Furthermore, higher soluble thrombomodu-
lin levels suggest the presence of extensive damage to
microvasculature endothelium. These changes are summa-
rized in Figure 3.
Thrombin generation in the systemic circulation
Thrombin generation is essential to control the four major
hemostatic domains, consisting of coagulation, anticoagu-
lation, fibrinolysis, and antifibrinolysis, and the endothelial
function deeply affects all four of these hemostatic systems
[65]. Under normal conditions, thrombin generation and
clot formation are localized to the site of the injured
vessels associated with these systems, as shown in the
cell-based model [28,65]. However, systemic inflamma-
tion caused by severe insults can alter the properties of
the four hemostatic systems by affecting the endothelial
function. Systemic thrombosis, namely DIC, ensues when
these changes overwhelm the anticoagulation mechanisms
that restrict the hemostasis locally [28,65].
Soluble fibrin and fibrinopeptide A are considered to
be accurate markers of thrombin generation and activity
because both of these are formed as a result of the direct
action of thrombin on fibrinogen, which is followed by
fibrin formation. Extremely elevated levels of fibrinopeptide
• Low TFPI
• Low antithrombin
• Low protein C
• Deficient protein S
• Loss of functional TM




Figure 3 The balance between thrombin generation and its inhibition. Disseminated intravascular coagulation occurs when there is an
imbalance between thrombin generation and its inhibition. Insufficient coagulation control mechanisms contribute to massive thrombin
generation in the circulation, which overwhelms activated protein C-mediated inhibition of thrombin generation. TFPI, tissue factor pathway
inhibitor; TM, thrombomodulin.
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to the emergency department have been described [61].
In addition, higher levels of these molecular markers of
thrombin generation at an early stage of trauma have
been repeatedly confirmed [5-7,47,48,53]. Dunbar and
Chandler demonstrated excessive non-wound-related
thrombin generation in trauma patients with both DIC
and ‘ACOTS’ immediately after arrival to the hospital
[63,64]. Their first study showed marked systemic throm-
bin generation due to circulating procoagulants that initi-
ate thrombin generation systemically as well as a reduced
ability to localize hemostasis at the wound site due to the
loss of antithrombin. Their second study found that
tissue factor activity made up approximately 80% of
the total procoagulant activity. Reports showing a signifi-
cant correlation between tissue factor and the markers of
thrombin generation and microparticle formation by
activated platelets support these results [66,67]. Importantly,
the term ‘ACOTS’ in the first study was changed to ‘DIC’ in
their second study [63,64].
The overall function of the thrombomodulin/protein
C anticoagulant pathway can be precisely evaluated by
examining the prothrombinase activity [68]. Prothrombi-
nase is a complex comprising FXa, FVa, phospholipids, and
Ca2+ and is the biggest determinant of thrombin generation
from prothrombin. The prothrombinase activity, measured
as the thrombin generation rate, decreases in proportion
to the amount of thrombin-thrombomodulin complex-
induced formation of activated protein C and the subse-
quent inactivation of FVa [68,69]. DIC patients after trauma
showed normal prothrombinase activity associated with
higher levels of soluble fibrin [62]. These results suggestthat the inhibition of the prothrombinase activity caused
by activated protein C-mediated anticoagulation does not
overwhelm the activation of the tissue factor-induced
systemic thrombin generation or its activation in trau-
matic DIC patients. This imbalance between thrombin
generation (soluble fibrin) and its inhibition (pro-
thrombinase activity) could be explained by an insuffi-
ciency in the other anticoagulant mechanisms, such as
TFPI and antithrombin, and a lower function of thrombo-
modulin due to endothelial injury, which were confirmed
in that study [62]. Importantly, all of the above-mentioned
results were also observed in patients diagnosed with
ACOTS [62].
Consumption coagulopathy
DIC has been recognized as a consumptive thrombohemor-
rhagic disorder [2]. Consumptive processes reflect the mul-
tiple actions of thrombin. Increased thrombin generation
accounts for decreases in platelets, fibrinogen, FII, FV,
FVIII, and FXIII in acute consumption, and the decreases
in other clotting factors, such as FIX and FX, are due to the
rapid clearance of activated clotting factors in vivo [2].
Thrombin induces the release of t-PA from endothelial
cells, followed by plasmin generation. If plasmin is formed
sufficiently in the circulation, it degrades fibrinogen,
FV, and FVIII. These lines of evidence support a rapid
consumption of thrombin-sensitive hemostatic factors,
including platelets, fibrinogen, and factors V, VIII, and XIII.
As a result of thrombin-mediated protein C activation, sen-
sitive and rapid decreases in the levels of FV and FVIII
have been demonstrated in pre-DIC and DIC cases [70,71].
In cases of DIC due to trauma, platelets are sometimes
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vessels and the release from storage in organs such as
the spleen, liver, and lungs [5,7,72]. FVIII is known to
paradoxically increase in response to clinical insults,
including trauma, due to release of von Willebrand
factor (VWF) from the endothelial Weibel-Palade bodies
[73] and the acute phase behavior of FVIII. The VWF im-
mediately interacts with FVIII, and this interaction pro-
longs the plasma half-life of FVIII [74]. The consumption
of coagulation factors prolongs both the prothrombin
time (PT) and APTT; however, the APTT sometimes is
normal or even shortened because of interactions between
FVIII with VWF in spite of a prolongation of the PT in
patients with DIC.
A prolonged PT, which reflects a decrease in FV and
to a lesser extent in factors II, VII, and X, and decreases
in fibrinogen levels immediately to several days after
trauma have been repeatedly confirmed in cases of
trauma with DIC [5,7,35,40,43,47,61,62,66]. A prolonged
APTT, which reflects a decrease in factors V, VIII, and
fibrinogen, has also been confirmed immediately after
trauma in patients with DIC [61]. FVII antigen has been
demonstrated to be consumed at a relatively slow speed for
about 8 hours in a rabbit model of DIC [75]. Importantly,
the FVIIa levels increased to 120% within 2 hours after the
induction of DIC and then declined. Furthermore, the
FXIII, α2-antiplasmin and fibronectin levels, which play
important roles in cross-linking fibrin formation and
wound healing, showed marked and rapid decreases in
DIC patients at arrival to the emergency department [76].
The consumption of coagulation factors, especially FV
and FVIII, is a basic principle of DIC in trauma, which
was confirmed several decades ago [77]. A recent principle
component analysis reconfirmed that global coagulation
factor consumption, as well as decreased protein C and
antithrombin levels, is associated with an increased
incidence of coagulopathy and the mortality of the pa-
tients [9].
Activation of fibrinolysis
DIC and pathological systemic fibrin(ogen)olysis sometimes
coexist following the same insult, including trauma, which
is called DIC with the fibrinolytic phenotype [2]. Traumatic
shock-induced tissue hypoperfusion causes t-PA release
from the endothelial Weibel-Palade bodies, which leads to
systemic fibrin(ogen)olysis in addition to DIC-induced
secondary fibrinolysis [2,73]. Increased fibrinolysis, as
well as the activation of coagulation in trauma, has
long been recognized [78,79]. Recently, these findings
were reconfirmed in severely injured trauma patients, 40%
of whom showed a PT ratio of more than 1.2 [80]. That
study demonstrated increased thrombin generation and
consumption of fibrinogen and antithrombin, as well as
increased t-PA, plasmin generation, and fibrinolysis alongwith consumption of α2-antiplasmin, all of which coincided
with DIC with the fibrinolytic phenotype.
The most important point in the pathogenesis of fibrin
(ogen)olysis at an early stage of trauma is that there is a
several hour time difference between the immediate
t-PA release from the endothelium and later expression
of PAI-1 mRNA, leading to an extreme imbalance of these
molecules [81-83]. Supporting this imbalance, the levels of
PAI-1 are almost identical in patients with and without
DIC immediately after trauma, whereas the levels of t-PA
and plasmin generation both were significantly increased
in patients with DIC [5,35,61,62].
In addition to plasmin, neutrophil elastase-mediated
fibrinolysis is involved in the pathogenesis of fibrin
(ogen)olysis in DIC with the fibrinolytic phenotype [47].
The lower levels of α2-antiplasmin, FXIII, and fibronectin
in patients with DIC suggest that there is insufficient
inhibition of plasmin, impaired cross-linking of fibrin, and
delayed wound healing, leading to fragile fibrin formation
associated with persistent bleeding [5,7,61,76]. A study
showing tissue factor-induced fibrin(ogen)olysis without
tissue hypoperfusion suggests that secondary fibrinolysis
caused by massive fibrin formation-induced t-PA re-
lease may also have a role in DIC with the fibrinolytic
phenotype [84]. Importantly, thrombomodulin-mediated
thrombin-activatable fibrinolysis inhibitor activation does
not have an important role in the pathogeneses of fibrin
(ogen)olysis immediately after trauma, which indirectly
supports that there is insufficient thrombomodulin/
protein C pathway. Therefore, activated protein C-mediated
inhibition of PAI-1 is unlikely [47,80].
Solving the mystery of microvascular thrombosis
Histological evidence of microvascular thrombosis in
DIC, especially in DIC with the thrombotic phenotype,
has been reported in clinical, experimental, and autopsy
findings [85]. However, this evidence of DIC with the
fibrinolytic phenotype is rarely available in humans and
was extensively debated during the 1960s and 1970s
[86]. These debates on the inconsistency of thrombus
formation had come about due to the existence of
hyperfibrin(ogen)olysis at an early stage of trauma and
traumatic shock. Although arguments had been proposed,
fibrin thrombosis [87], vein thrombi formation [88],
platelet aggregation, and emboli formation [89,90] had
been repeatedly confirmed in hemorrhagic shock and
trauma. Subsequently, the platelet and fibrin thrombosis
became more prominent during antifibrinolytic therapy
using tranexamic acid in a dog model of hemorrhagic
shock [91] (Figure 4). It should be emphasized that the
article expressing negative opinions about DIC had been
forced to conclude that some fibrin thrombi were
observed in their histological study [92]. Importantly, signs
of inflammation, microthrombus, and embolus formation
Figure 4 The inhibition of the activation of fibrinolysis by
tranexamic acid revealed microvascular thrombosis and
thromboemboli formation in the large vessels in a dog model
of hemorrhagic shock. (A) A section of a branch of the portal vein
almost completely filled by a mixed thrombus consisting of platelets
and fibrin threads in bundles. (B) A section from lung vessels with
thrombotic masses consisting of both platelets and fibrin thread.
Phosphotungstic acid hematoxylin staining. Adapted with
permission from Leandoer and Bergentz [91].
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studies [93,94]. As it is clearly understood according to the
definition of DIC proposed by the SSC on DIC of ISTH, it
is of limited interest to discuss whether microvascular
thrombosis occurs in a situation of fibrin(ogen)olysis
immediately after trauma and traumatic shock. However,
it is important to recognize the coexistence of pro- and
anti-thrombotic states during the early stage of trauma.
Therefore, the debate on microvascular thrombosis has
major implications for the therapeutic strategies for
patients with DIC after trauma [95].
Animal models
Animal models of trauma have their limitations, and the
findings in animals may not directly mimic the situation
in trauma patients. Two review articles identified a
general lack of experimental research to keep pace
with the research on human trauma [96,97]. Differences
in the coagulation systems between different species are
also an important issue. Porcine models are relatively
hypercoagulable and have only 36% of the levels of protein
C [97]. Many different kinds of trauma models have been
used in experimental animal studies, which have resulted
in diverse interpretations of trauma-induced coagulopathy
[96,97]. However, under these circumstances, the super-
iority of the polytrauma and shock model has recently
been reported [98].
The Noble-Collip drum-induced polytrauma and
traumatic shock uncomplicated by gross hemorrhage
have been used by numerous investigators to mimic
lethal traumatic injury. Noble-Collip drum trauma
and shock could immediately reproduce typical DIC
with the fibrinolytic phenotype, with animals exhibiting
decreases in platelet counts, the prolongation of the PT
and APTT, decreases in fibrinogen and antithrombin, andelevation of the fibrin/fibrinogen degradation products
[99,100]. Furthermore, the elevation of t-PA, shortening
the euglobulin lysis time, and decrease in α2-antiplasmin
indicated the immediate activation of the fibrinolytic
system [100]. Decreases in the levels of FXII, prekallikrein,
and CH50 suggested the activation of both the intrinsic
coagulation pathway and the complement system [100].
Immediately after Noble-Collip drum trauma and shock,
tissue factor increases in the circulation and its mRNA
expression has been observed in various organs, indicating
the activation of the extrinsic coagulation pathway [101].
Tissue factor-induced DIC model has been reported to
be a ‘grade A’ relevant experimental model for trauma
[96]. This model demonstrated that a massive amount of
tissue factor induces DIC associated with fibrin(ogen)
olysis without tissue hypoperfusion [84]. This result sug-
gests that trauma itself could give rise to DIC without
tissue hypoperfusion, thus supporting the results of a pre-
vious clinical study [47]. Tissue factor-induced activation
of coagulation leads to generalized consumption of not
only coagulation factors but also of the inhibitory feedback
factors involved in controlling coagulation and fibrinolysis,
namely antithrombin and α2 antiplasmin, respectively.
Lower levels of antithrombin enhance thrombin generation,
and a decrease in the level of α2 antiplasmin is another im-
portant factor involved in the pathogenesis of hyperfibrin
(ogen)olysis, which is in agreement with the results of
clinical studies [63,64,76].
Conclusions
The main pathophysiological mechanism underlying the
hemostatic changes that occur following trauma and
traumatic shock is DIC with the fibrinolytic phenotype.
This is associated with activation of coagulation, insufficient
control of coagulation, fibrin(ogen)olysis, and consumption
coagulopathy, leading to oozing-type bleeding at mucosal
lesions, serosal surfaces, and surgical-site wounds, which
affect the prognosis of trauma patients. The pathogenesis of
DIC with the fibrinolytic phenotype is due to the dys-
regulation of local hemostasis and immunothrombosis
that are overwhelmed by the systemic inflammation
caused by extensive tissue injury and tissue hypoperfusion.
Traumatic shock-induced hypoperfusion and fibrin thrombi
give rise to primary and secondary fibrin(ogen)olysis due to
the t-PA released from the endothelium. The coexistence
of hypothermia, acidosis, and dilution aggravates DIC
with the fibrinolytic phenotype and then leads to so-called
trauma-induced coagulopathy.
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